P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

Liknande verk

• Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
  av: Moritz Fürstenau, et al.
  Utgiven: (2019-11-01)
• The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG)
  av: Nadine Kutsch, et al.
  Utgiven: (2024-07-01)
• Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease
  av: Esther Domingo, et al.
  Utgiven: (2010-04-01)
• NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL
  av: Shrihari S. Kadkol, et al.
  Utgiven: (2021-01-01)
• P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
  av: Florian Simon, et al.
  Utgiven: (2023-08-01)